Natera Surges to 249th Most Traded Stock with $309 Million Turnover

On June 18, 2025, Natera (NTRA) experienced a significant surge in trading volume, with a turnover of $309 million, marking a 105.73% increase from the previous day. This substantial rise in trading activity positioned Natera as the 249th most traded stock of the day. The stock price of Natera also saw a notable increase, rising by 1.98%.

Natera, a leading company in cell-free DNA and precision medicine, recently announced that its Signatera Genome assay has been approved for Medicare coverage. This development is expected to enhance the accessibility and affordability of the Signatera test, which is used for minimal residual disease (MRD) detection in cancer patients. The approval underscores the clinical utility and effectiveness of the Signatera assay in monitoring cancer treatment and detecting early signs of recurrence.

In addition to the Medicare coverage, Natera showcased the clinical performance of its Signatera Genome assay at the American Society of Clinical Oncology (ASCO) 2025 conference. The results from a large-scale pan-cancer study demonstrated the assay's high sensitivity and specificity in detecting MRD across various cancer types. This presentation further solidified Natera's position as a pioneer in precision medicine and cancer diagnostics.

Natera's first-quarter 2025 financial results revealed strong revenue growth and earnings per share (EPS) that exceeded market expectations. The company's flagship product, Signatera, contributed significantly to this growth, driven by increasing demand for its MRD testing capabilities. Management expressed optimism about the future prospects of Signatera, citing its potential to revolutionize cancer treatment and monitoring.

Natera is set to present data from over 25 Signatera studies at the 2025 ASCO Annual Meeting, highlighting the extensive research and development efforts behind its precision medicine solutions. The company's commitment to innovation and clinical validation is evident in its continuous efforts to expand the applications of its Signatera assay and improve patient outcomes.